GlassScriptPhysician profile
Amber Joy Ewonce
NPI 1902420961
$3,753.28
in general payments reported to CMS, 2019-2025
19 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $62.64 · 2021: $225 · 2022: $733 · 2023: $1,800 · 2024: $502 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,285.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,549.18 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $373.15 | 2021-2025 | Rocklatan, Precision7, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $318.08 | 2022-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Vision Care, INC. | $301.11 | 2020-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $201.49 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $137.38 | 2022-2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $114.30 | 2023 | Syfovre |
| Glaukos Corporation | $112.89 | 2022 | |
| Allergan, INC. | $102.94 | 2022 | |
| Sun Pharmaceutical Industries INC. | $98.22 | 2020-2025 | Cequa |
| Abbvie INC. | $86.26 | 2022-2023 | |
| Lkc Technologies, INC. | $85.05 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $77.42 | 2020-2023 | |
| Harrow Eye, LLC | $49.66 | 2024 | Vevye |
| Dompe US, INC. | $45.05 | 2024-2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $39.97 | 2021 | |
| Thea Pharma INC. | $23.49 | 2024 | Iyuzeh |
| Oyster Point Pharma, INC. | $21.42 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Ewonce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.